Clinical practice guideline on the pharmacological management of antipsychotic-related dyslipidemia

Simple item page
dc.contributor.authorCarolan, Aoifeen
dc.contributor.authorHynes-Ryan, Carolineen
dc.contributor.authorBourke, Ritaen
dc.contributor.authorColumb, Daviden
dc.contributor.authorCullen, Walteren
dc.contributor.authordeFerranti, Sarahen
dc.contributor.authorHarrington, Sophie Maeen
dc.contributor.authorKelleher, Ianen
dc.contributor.authorKennedy, Cormacen
dc.contributor.authorKhoury, Michaelen
dc.contributor.authorLally, Johnen
dc.contributor.authorLyne, Johnen
dc.contributor.authorNorton, Michaelen
dc.contributor.authorO’Connor, Karenen
dc.contributor.authorO’Connor, Patriciaen
dc.contributor.authorO’Shea, Donalen
dc.contributor.authorPerry, Benjaminen
dc.contributor.authorPrendeville, Terenceen
dc.contributor.authorRyan, Cristinen
dc.contributor.authorSadowska, Ewaen
dc.contributor.authorShiers, Daviden
dc.contributor.authorSiskind, Danen
dc.contributor.authorStrawbridge, Judithen
dc.contributor.authorTae, Haeunen
dc.contributor.authorKeating, Doloresen
dc.contributor.authorO’Donoghue, Brianen
dc.contributor.funderHealth Research Boarden
dc.date.accessioned2026-09-11T13:42:03Z
dc.date.available2026-09-11T13:42:03Z
dc.date.issued2026-08-03en
dc.description.abstractBackground: People taking antipsychotic medicines and those with severe mental illness experience elevated cardiovascular risk compared to the general population which is not adequately addressed by existing guidelines. Increases in lipid levels can occur soon after starting antipsychotics but often go untreated. Cumulative exposure to dyslipidemia from childhood, through young adulthood, facilitates atherogenesis. Regression of early lesions is possible; however, plaque progression can be irreversible, leading to sustained long-term cardiovascular risk. Although lipid-lowering therapies are effective at lowering cardiovascular risk, they are underutilized in this population. We have thus developed a clinical practice guideline for the pharmacological management of antipsychotic-related dyslipidemia. Study Design: Using GRADE-ADOLOPMENT methodology, an international, multidisciplinary panel including experts-by-experience, developed a guideline for the pharmacological management of antipsychotic-related dyslipidemia. Literature was reviewed to answer key health questions. Patient important outcomes were identified. An evidence-to-decision framework informed the strength of recommendations and external reviews evaluated the rigor of the methods. Study Results: Seven recommendations were developed on how and when to initiate lipid-lowering therapy based on specific criteria including established cardiovascular disease/high-risk conditions, cardiovascular risk assessment, or lipid parameter thresholds. A guideline algorithm illustrates the recommendations alongside supporting prescribing information. Conclusions: This is the first clinical practice guideline for the management of antipsychotic-related dyslipidemia. The inclusion of recommendations for individuals aged 10 years and over represents a significant development. Implementation will be supported by shared decision-making resources including information videos and decision-aids.en
dc.description.sponsorshipHealth Research Board|APRO-2023-005en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleidsbag086en
dc.identifier.citationCarolan, A., Hynes-Ryan, C., Bourke, R., Columb, D., Cullen, W., deFerranti, S., Harrington, S. M., Kelleher, I., Kennedy, C., Khoury, M. and Lally, J. (2026) 'Clinical practice guideline on the pharmacological management of antipsychotic-related dyslipidemia', Schizophrenia Bulletin, 52(4), sbag086 (13pp). https://doi.org/10.1093/schbul/sbag086en
dc.identifier.doi10.1093/schbul/sbag086en
dc.identifier.endpage13en
dc.identifier.issn0586-7614en
dc.identifier.issn1745-1701en
dc.identifier.issued4en
dc.identifier.journaltitleSchizophrenia Bulletinen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/19240
dc.identifier.volume52en
dc.language.isoenen
dc.publisherOxford University Press (OUP)en
dc.relation.projectinfo:eu-repo/grantAgreement/HRB/Applied Programme Grants::Projects and Programmes/APRO-2023-005/IE/Achieving recovery in psychotic disorders with comprehensive clinical guidelines/en
dc.rights© 2026, the author(s). Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.comen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectAntipsychotic medicinesen
dc.subjectElevated cardiovascular risken
dc.subjectClinical practice guidelineen
dc.titleClinical practice guideline on the pharmacological management of antipsychotic-related dyslipidemiaen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
sbag086.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
Thumbnail Image
Name:
supplementary_material_v_2_sbag086.docx
Size:
1.68 MB
Format:
Microsoft Word XML
Description:
Supplementary Data
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
School of Medicine